Advertisement

Intensive Care Medicine

, Volume 20, Supplement 3, pp S14–S20 | Cite as

Pharmacokinetic characteristics of piperacillin/tazobactam

  • F. Sörgel
  • M. Kinzig
Article

Abstract

Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin combined with tazobactam were similar to those of piperacillin alone. In contrast, tazobactam administered with piperacillin achieved higher plasma concentrations and had a longer half-life than tazobactam administered alone. Intravenous infusion of 4.0 g piperacillin with 0.5 g tazobactam over 5 min resulted in mean maximum plasma concentrations of 380 μg piperacillin/ml and 35.3 μg tazobactam/ml; half-lives were 1.14 h for piperacillin and 0.92 h for tazobactam. Within 30 min of infusion, piperacillin/tazobactam achieves 16–85% of plasma concentrations in skin, muscle, lung, gallbladder, and intestinal mucosa. Plasma and tissue levels remain above the MIC90s of major pathogens for 2 h post administration. These findings show that piperacillin/tazobactam is a truly synergistic combination which can be expected to be effective in treating a wide variety of infections in the clinical setting.

Key words

Piperacillin Beta-lactamases Pharmacokinetics 

References

  1. 1.
    Gutman L, Kitzis MD, Yamabe S, Acar JF (1986) Comparative evaluation of a new β-lactamase inhibitor, YTR 830, combined with different β-lactam antibiotics against bacteria harboring known β-lactamases. Antimicrob Agents Chemother 29:955–957Google Scholar
  2. 2.
    Jacobs MR, Aronoff SC, Johenning S, Yamabe S (1986a) Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined β-lactamase-producing aerobic gramnegative bacilli. Antimicrob Agents Chemother 29:980–985Google Scholar
  3. 3.
    Jacobs MR, Aronoff SC, Johenning S, Yamabe S (1986b) Comparative activities of the β-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistentEnterobacteriaceae and pseudomonas. J Antimicrob Chemother 18:177–184Google Scholar
  4. 4.
    Kern W, Kennedy SL, Sachdeva M, Sande ER, Gunderson D, Täuber MG (1990) Evaluation of piperacillin-tazobactam in experimental meningitis caused by a β-lactamase-producing strain of K1-positiveEscherichia coli. Antimicrob Agents Chemother 34:697–700Google Scholar
  5. 5.
    Gould IM, Ansari A, Harvey G, Douglas JG, Smith CC, Reid TM (1991) Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Drugs Exp Clin Res 17:187–190Google Scholar
  6. 6.
    Kinzig M, Sörgel F, Brismar B, Nord CE (1992) Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother 36:1997–2004Google Scholar
  7. 7.
    Muth P, Kinzig M, Kujath P, Sörgel F (1991) Determination of tazobactam levels in human plasma and tissue using a HPLC column switching technique. J Chemother [Suppl 4]:227–228Google Scholar
  8. 8.
    Fortner CL, Finley RS, Schimpff SC (1982) Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy 2:287–299Google Scholar
  9. 9.
    Holmes B, Richards DM, Brogden RN, Heel RC (1984) Piperacillin — a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 28:375–425Google Scholar
  10. 10.
    Seelmann R, Sörgel F, Wiesemann HG, Grüner A, Stephan U (1987) New aspects of piperacillin's pharmacokinetics in man. Proceedings of the Fifteenth International Congress of Chemotherapy, Istanbul, Turkey, 1987. In: Kuemmerle HP (ed) Progress of antimicrobial and anticancer chemotherapy. Ecomed, Landsberg/Lech, Germany, pp 961–963Google Scholar
  11. 11.
    Sörgel F, Stephan U, Lang E, Geldmacher-von Mallinckrodt M, Seelmann R, Wiesemann HG (1986) Pharmacokinetik von Piperacillin im Vergleich. In: Adam D, Knothe H, Stille W (eds) In Paul-Ehrlich-Gesellschaft. Piperacillin, Fortschritte der antimikrobiellen antineoplastischen Chemotherapie FAC 5-6. Futuramed, Munich, Germany, pp 921–937Google Scholar
  12. 12.
    Sörgel F, Seelmann R, Stephan U (1988) Comparative pharmacokinetics of apalcillin, mezlocillin, and piperacillin in healthy volunteers. Proceedings of the First Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Munich, Germany, 1987. In: Adam D, Hiddemann W (eds) Paul-Ehrlich-Gesellschaft. J Chemother Inf Dis Malig ZAC 6 [Suppl 1], Futuramed, Munich, Germany, pp 157–158Google Scholar
  13. 13.
    Cheung WK, Greene DS, Kuye O, Shin KJ, Tonelli AP, Houston A et al (1988a) Pharmacokinetics of YTR 830 and piperacillin after intravenous coadministration. Proceedings of the Sixth Mediterranean Congress of Chemotherapy, Taormina, Italy, 1988. Abstr. 159Google Scholar
  14. 14.
    Cheung WK, Greene DS, Kuye O, Smith MPJ, Holder A, Fernandez P et al. (1988b) Pharmacokinetics of YTR 830 in healthy human subjects. Proceedings of the Sixth Mediterranean Congress of Chemotherapy, Taormina, Italy, 1988. Abstr. 158Google Scholar
  15. 15.
    Ganes D, Batra V, Faulkner R, Greene D, Haynes J, Kuye O et al (1991) Effect of probenecid on the pharmacokinetics of piperacillin and tazobactam in healthy volunteers. Proceedings of the Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington DC. Pharmaceut Res 8:S-299. Abstr. PPDM 8293Google Scholar
  16. 16.
    Weiss W, Jacobus N, Petersen P, Testa R, Tally F (1989) Bactericidal and β-lactamase inhibitory activity of piperacillin/tazobactam. In: Piperacillin and tazobactam. Proceedings of the Sixteenth International Congress of Chemotherapy, Jersualem, Israel, June 11–16, 1989Google Scholar
  17. 17.
    Wu WH, Greene DS, Kuye O et al (1989) Pharmacokinetic observations with piperacillin/tazobactam and their relevance to dosage decisions. In: Piperacillin and tazobactam. Proceedings of the Sixteenth International Congress of Chemotherapy, Jerusalem, Israel, June 11–16, 1989Google Scholar
  18. 18.
    Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A et al (1992) Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharm Ther 51:32–41Google Scholar
  19. 19.
    Wu WH, Greene DS, Kuye O, Ruffner A, Höffler D, Haynes J et al (1991) Pharmacokinetics of piperacillin/tazobactam (4/1) after a single infusion in renal impaired patients. Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington, DC. Pharmaceutical Res 8:S-303. Abstr. PPDM 8357Google Scholar
  20. 20.
    Lathia C, Sia L, Lanc R, Greene D, Kuye O, Batra V et al (1991 b) Pharmacokinetics of piperacillin/tazobactam IV with and without tobramycin IV in healthy adult male volunteers. Sixth Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Washington DC. Pharmaceut Res 8:S-303. Abstr. PPDM 8310Google Scholar
  21. 21.
    Tulkens PM (1990) Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data. Proceedings of the Symposium in Stockholm, Sweden, Bohusläningens Boktryckeri AB, Uddevalla, Sweden, pp 249–257Google Scholar
  22. 22.
    Drusano GL (1991) Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis [Suppl 74]:235–248Google Scholar
  23. 23.
    American Cyanamid, Data on FileGoogle Scholar
  24. 24.
    Sörgel F, Kinzig M, Naber KG (1993) Physiological disposition of macrolides. In: Bryskier A, Butzler JP, Neu HC, Tulkens PM (eds) Macrolides-chemistry, pharmacology and clinical uses. Blackwell, Paris, France, pp 421–435Google Scholar
  25. 25.
    Kinzig M, Sörgel F, Naber KG, Müller C (Oct 11–14, 1992) Penetration of erythromycin ethylsuccinate (EES), erythromycin (E), and new macrolides (MAC) into extracellular fluids (ECF) — a tool to study unresolved questions of macrolide pharmacokinetics. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, Ca (USA), Abstr. 217Google Scholar
  26. 26.
    Kinzig M, Muth P, Kujath P, Ebert J, Mahr G, Sörgel F et al (1991 a) Pharmacokinetics and tissue penetration of tazobactam/piperacillin in man. Proceedings of the Seventeenth International Congress of Chemotherapy, Berlin, Germany, Abstr. 949Google Scholar
  27. 27.
    Kinzig M, Sörgel F, Naber KG, Kujath P, Nord CE, Brismar B et al (1991 b) Tissue penetration of piperacillin/tazobactam. Proceedings of the thirty-first Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago Illinois, Abstr. 862. American Society for Microbiology, Washington, DCGoogle Scholar
  28. 28.
    Naber KG, Sörgel F, Kinzig M, Weigel D (1991) Penetration of piperacillin/tazobactam into prostatic tissue and secretion of elderly patients. Proceedings of the Seventeenth International Congress of Chemotherapy, Berlin, Germany, Abstr. 951Google Scholar
  29. 29.
    Wise R, Logan M, Cooper M, Andrews JM (1991) Pharmacokinetics macokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 35:1081–1084Google Scholar
  30. 30.
    Fass RJ, Prior RB (1989) Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 33:1268–1274Google Scholar
  31. 31.
    Sörgel F, Kinzig M (1993) The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31 [Suppl A]:39–60Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • F. Sörgel
    • 1
  • M. Kinzig
    • 1
  1. 1.IBMPInstitute for Biomedical and Pharmaceutical ResearchNürnberg-HeroldsbergGermany

Personalised recommendations